Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 440 | 48 | 390 |
| Samples | 132 | 21 | 109 |
| Peptides | 89 | 13 | 76 |
Function
RPL8 · Ribosomal protein L8
Ribosomes, the organelles that catalyze protein synthesis, consist of a small 40S subunit and a large 60S subunit. Together these subunits are composed of 4 RNA species and approximately 80 structurally distinct proteins. This gene encodes a ribosomal protein that is a component of the 60S subunit. The protein belongs to the L2P family of ribosomal proteins. It is located in the cytoplasm. In rat, the protein associates with the 5.8S rRNA, very likely participates in the binding of aminoacyl-tRNA, and is a constituent of the elongation factor 2-binding site at the ribosomal subunit interface. Alternatively spliced transcript variants encoding the same protein exist. As is typical for genes encoding ribosomal proteins, there are multiple processed pseudogenes of this gene dispersed through the genome. [provided by RefSeq, Jul 2008].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 83 amino-acid changes on canonical ENST00000528957 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RPL8 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RPL8 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Mesothelioma | 2/62 3% | 0/165 0% |
| Kidney Carcinoma | 2/85 2% | 14/1862 1% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 1/133 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 5/752 1% |
| Ewings Sarcoma | 2/63 3% | 0/262 0% |
| Endometrial Carcinoma | 0/42 0% | 4/612 1% |
| Other Solid Cancers | 2/94 2% | 7/1515 0% |
| Non-Small Cell Lung Carcinoma | 1/304 0% | 8/1390 1% |
| Colorectal Carcinoma | 3/143 2% | 14/3239 0% |
| Bladder Carcinoma | 0/58 0% | 5/956 1% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 4/810 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Melanoma | 1/210 0% | 8/1899 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Esophageal Carcinoma | 0/23 0% | 2/769 0% |
| Prostate Carcinoma | 2/13 15% | 3/2105 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 5/2550 0% |
| Ovarian Carcinoma | 1/109 1% | 1/998 0% |
| Pancreatic Carcinoma | 0/89 0% | 3/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Neuroendocrine Tumour | 0/154 0% | 1/577 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Breast Carcinoma | 1/144 1% | 3/3264 0% |
| Non-Cancerous | 0/104 0% | 1/830 0% |
| Gastric Carcinoma | 0/74 0% | 2/1809 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 1/2534 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Glioma | 0/52 0% | 1/2127 0% |
Mutation Distribution
Where RPL8 is mutated · all tissues, split by cell line vs tissue
How many mutations in RPL8 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 440 mutations in RPL8
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|